# Xuanzhu Biopharmaceutical Co., Ltd. trials: 24 (2026)

ClinicalTrials.gov lists 24 trials with Xuanzhu Biopharmaceutical Co., Ltd. as lead sponsor, 9 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Xuanzhu Biopharmaceutical Co., Ltd.: 24 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/xuanzhu-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 26, 2026 | NCT07606833 | The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing... | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | HELICOBACTER PYLORI INFECTIONS | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606833) |
| January 16, 2026 | NCT07345689 | A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | Hepatic Insufficiency, Renal Insufficiency, Elderly | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07345689) |
| January 9, 2026 | NCT07330531 | Drug-drug Interaction Study of Rifampin and Anaprazole Sodium | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 4 | Not yet recruiting | Drug-drug Interaction Study | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330531) |
| June 8, 2025 | NCT07010107 | A Clinical Trial of Anaprazole for Treating Reflux Esophagitis. | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Reflux Esophagitis (RE) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010107) |
| May 1, 2023 | NCT05836805 | A Study of the Absorption, Metabolism and Excretion of \[14C\]XZP-3621 in Human | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05836805) |
| April 7, 2023 | NCT05804864 | A Study of KM501 in Patients With Solid Tumors | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumors | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05804864) |
| March 16, 2023 | NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor, NSCLC | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05772455) |
| March 13, 2023 | NCT05766527 | A Study of KM602 in Patients With Advanced Solid Tumors | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumor | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05766527) |
| February 23, 2023 | NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | AML, MDS | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05740917) |
| November 3, 2022 | NCT05604261 | A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis, Esophageal Motility Disorders, Deglutition Disorders... | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05604261) |
| October 19, 2022 | NCT05586568 | Drug-drug Interaction Study of XZP-3621 Tablet | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy Subjects | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05586568) |
| August 1, 2022 | NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | ALK-positive NSCLC | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05482087) |
| July 28, 2022 | NCT05478109 | A Clinical Trial of XZP-3287 for Material Balance | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy Male Subjects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05478109) |
| April 11, 2022 | NCT05320874 | A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Advanced Solid Tumor | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05320874) |
| February 25, 2022 | NCT05257395 | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Advanced Breast Cancer | 397 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05257395) |
| January 24, 2022 | NCT05204628 | A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Unknown | Non-small Cell Lung Cancer | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05204628) |
| October 14, 2021 | NCT05077449 | A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Advanced Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05077449) |
| October 1, 2021 | NCT05063968 | A Clinical Trial of XZP-6019 Tablets in Healthy Subjects | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Non-alcoholic Fatty Liver Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05063968) |
| September 24, 2021 | NCT05055232 | A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Completed | ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05055232) |
| September 5, 2021 | NCT05034120 | Food Effect and Mass Balance Study of XZP-3621 Tablets | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05034120) |
| August 9, 2021 | NCT04996121 | A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04996121) |
| July 7, 2021 | NCT04951765 | Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04951765) |
| July 7, 2021 | NCT04951713 | Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04951713) |
| June 4, 2021 | NCT04913090 | A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 | Unknown | Nonalcoholic Steatohepatitis (NASH) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04913090) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 5 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 11 |
| Not yet recruiting | 6 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Completed | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Esophagitis, Peptic | 2 |
| Hepatic Insufficiency | 1 |
| Renal Insufficiency | 1 |
| Gastroesophageal Reflux | 1 |
| Esophagitis | 1 |
| Esophageal Motility Disorders | 1 |
| Deglutition Disorders | 1 |
| Esophageal Diseases | 1 |
| Gastrointestinal Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Engineering firms in the United States](https://specstream.ai/data/businesses/engineering-firms/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
